Emerging pharmaceutical therapies for osteoarthritis.

Abstract

The prevalence of osteoarthritis (OA) and the burden associated with the disease are steadily increasing worldwide, representing a major public health challenge for the coming decades. The lack of specific treatments for OA has led to it being recognized as a serious disease that has an unmet medical need. Advances in the understanding of OA pathophysiology have enabled the identification of a variety of potential therapeutic targets involved in the structural progression of OA, some of which are promising and under clinical investigation in randomized controlled trials. Emerging therapies include those targeting matrix-degrading proteases or senescent chondrocytes, promoting cartilage repair or limiting bone remodelling, local low-grade inflammation or Wnt signalling. In addition to these potentially disease-modifying OA drugs (DMOADs), several targets are being explored for the treatment of OA-related pain, such as nerve growth factor inhibitors. The results of these studies are expected to considerably reshape the landscape of OA management over the next few years. This Review describes the pathophysiological processes targeted by emerging therapies for OA, along with relevant clinical data and discussion of the main challenges for the further development of these therapies, to provide context for the latest advances in the field of pharmaceutical therapies for OA.

• Authors: Augustin Latourte, Margreet Kloppenburg, Pascal Richette
• Journal: Nature reviews. Rheumatology (Nat Rev Rheumatol) Vol. 16 Issue 12 Pg. 673-688 (12 2020) ISSN: 1759-4804 [Electronic] United States
• PMID: 33122845 (Publication Type: Journal Article, Review)

Topics

• Cartilage Diseases (complications, drug therapy, physiopathology)
• Health Services Needs and Demand
• Humans
• Osteoarthritis (complications, drug therapy, physiopathology)
• Pain (drug therapy, etiology)